Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 238.

https://doi.org/10.1182/blood-2024-192995

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Blood (2024) 144 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2024-199577

Published: 2024

Journal Articles

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Jennifer L. Crombie, Christine E. Ryan, Yue Ren, Svitlana Tyekucheva, Celeste Carey, Aaron Zou, Samantha Normilus, Josie Montegaard, Jacob D. Soumerai, Shruti Bhandari, Jon E. Arnason, Alvaro J Alencar, Austin I. Kim, Erin M. Parry, Philippe Armand, David C. Fisher, Jennifer R. Brown, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 4628.

https://doi.org/10.1182/blood-2024-199234

Published: 2024

Journal Articles

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Blood (2024) 144 (Supplement 1): 4409.

https://doi.org/10.1182/blood-2024-198687

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Blood (2024) 144 (Supplement 1): 4408.

https://doi.org/10.1182/blood-2024-198056

Published: 2024

Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2024) 144 (Supplement 1): 1865.

https://doi.org/10.1182/blood-2024-206556

Published: 2024

Journal Articles

Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

Blood (2024) 144 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2024-203414

Published: 2024

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies

Fen Zhu, Jing Wang, Christine E. Ryan, Liam Hackett, Jeremy Zhang, Stephen Jun Fei Chong, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 1615.

https://doi.org/10.1182/blood-2024-205802

Published: 2024

Journal Articles

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2024-194601

Published: 2024

Journal Articles

Is rituximab retro in mantle cell lymphoma?

Christine E. Ryan, Jonathon B. Cohen

Blood (2024) 144 (3): 241–243.

https://doi.org/10.1182/blood.2024024711

Published: 2024

Journal Articles

Frontline Treatment of Mantle Cell Lymphoma

Christine E Ryan, Philippe Armand, Ann S LaCasce

Blood blood.2023022352.

https://doi.org/10.1182/blood.2023022352

Published: 2024

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2023-173103

Published: 2023

Journal Articles

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Christine E. Ryan, Jennifer L. Crombie, Svitlana Tyekucheva, Mikaela M. McDonough, Josie S. Montegaard, Austin I. Kim, Jacob D. Soumerai, Alvaro J. Alencar, Shruti Bhandari, David C. Fisher, Jennifer R. Brown, Matthew S. Davids

Blood (2022) 140 (Supplement 1): 9871–9872.

https://doi.org/10.1182/blood-2022-169986

Published: 2022

Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2022) 140 (Supplement 1): 837–838.

https://doi.org/10.1182/blood-2022-168003

Published: 2022

Journal Articles

Inhibition of PRMT5 Increases Sensitivity to BH3 Mimetics in Aggressive B Cell Malignancies

Fen Zhu, Christine E. Ryan, Liam R. Hackett, Mary C Collins, Stephen Jun Fei Chong, Matthew S. Davids

Blood (2022) 140 (Supplement 1): 8842–8843.

https://doi.org/10.1182/blood-2022-167309

Published: 2022

Journal Articles

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori Leslie, John M. Pagel, Krish Patel, Anders Osterborg, Daniel Wojenski, Manali Kamdar, Scott F. Huntington, Matthew S. Davids, Jennifer R. Brown, Darko Antic, Ryan Jacobs, Inhye E. Ahn, Jeffrey Pu, Krista M. Isaac, Paul M. Barr, Chaitra S. Ujjani, Mark B. Geyer, Ellin Berman, Andrew D. Zelenetz, Nikita Malakhov, Richard R. Furman, Michael Koropsak, Neil Bailey, Lotta Hanson, Guilherme F. Perini, Shuo Ma, Christine E. Ryan, Adrian Wiestner, Craig A. Portell, Mazyar Shadman, Elise A. Chong, Danielle M. Brander, Suchitra Sundaram, Amanda N. Seddon, Erlene Seymour, Meera Patel, Nicolas Martinez-Calle, Talha Munir, Renata Walewska, Angus Broom, Harriet Walter, Dima El-Sharkawi, Helen Parry, Matthew R. Wilson, Piers E. M. Patten, José-Ángel Hernández-Rivas, Fatima Miras, Noemi Fernández Escalada, Paola Ghione, Chadi Nabhan, Sonia Lebowitz, Erica Bhavsar, Javier López-Jiménez, Daniel Naya, Jose Antonio Garcia-Marco, Sigrid S. Skånland, Raul Cordoba, Toby A. Eyre

Blood (2020) 136 (10): 1134–1143.

https://doi.org/10.1182/blood.2020006965

Published: 2020

Includes: Supplemental data

Journal Articles

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT

Christine E. Ryan, Bita Sahaf, Aaron C. Logan, Susan O’Brien, John C. Byrd, Peter Hillmen, Jennifer R. Brown, Martin J. S. Dyer, Anthony R. Mato, Michael J. Keating, Samantha Jaglowski, Fong Clow, Andrew R. Rezvani, Lori Styles, Steven E. Coutre, David B. Miklos

Blood (2016) 128 (25): 2899–2908.

https://doi.org/10.1182/blood-2016-06-715284

Published: 2016

Includes: Supplemental data

Journal Articles

Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis

Aaron C. Logan, MDPhD, Alex F. Herrera, MD, Christine E. Ryan, Andrew R. Rezvani, MD, Katherine A. Kong, PhD, Malek Faham, MD PhD, Gheath Alatrash, DO, PhD, Jeffrey J. Molldrem, MD, Rachel L. Sargent, MD, Edwin P. Alyea, MD, Vincent T. Ho, MD, Jennifer R. Brown, MD PhD, Jerome Ritz, MD, David B. Miklos, MD PhD

Blood (2015) 126 (23): 4340.

https://doi.org/10.1182/blood.V126.23.4340.4340

Published: 2015

NARROW

Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Is rituximab retro in mantle cell lymphoma?

Frontline Treatment of Mantle Cell Lymphoma

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Inhibition of PRMT5 Increases Sensitivity to BH3 Mimetics in Aggressive B Cell Malignancies

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT

Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only